Who
Jonathan Slonin
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Pacira BioSciences.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $773K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Aug 2021
- Last trade
- 17 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 18 Aug 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $71K3,040 at $23.23 | filing |
| 17 Aug 2026filed 18 Aug 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $71K3,040 at $23.23 | filing |
| 3 Jun 2026filed 5 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $106K4,728 at $22.32 | filing |
| 3 Jun 2026filed 5 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $106K4,728 at $22.32 | filing |
| 17 Mar 2026filed 19 Mar 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $74K3,261 at $22.82 | filing |
| 17 Mar 2026filed 19 Mar 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $74K3,261 at $22.82 | filing |
| 11 Feb 2026filed 13 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —54,546 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —54,546 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $127K6,168 at $20.54 | filing |
| 30 Jan 2026filed 3 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $127K6,168 at $20.54 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $9,319381 at $24.46 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $9,319381 at $24.46 | filing |
| 17 Nov 2025filed 19 Nov 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $95K3,960 at $24.09 | filing |
| 1 Aug 2025filed 4 Aug 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $6,952315 at $22.07 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $134K5,084 at $26.40 | filing |
| 1 Feb 2025filed 4 Feb 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —93,600 at $0.00 | filing |
| 6 Jan 2025filed 6 Jan 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $16K879 at $18.40 | filing |
| 2 Jan 2025filed 6 Jan 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $6,800371 at $18.33 | filing |
| 2 Aug 2024filed 2 Aug 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $19K945 at $20.05 | filing |
| 1 Aug 2024filed 2 Aug 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $6,329305 at $20.75 | filing |
News
No headline names them, or the companies they trade most, lately.